Natixis Vertex Pharmaceuticals Inc Transaction History

Natixis

$17.4 Billion
Q2 2024

A detailed history of Natixis transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Natixis holds 44,332 shares of VRTX stock, worth $22.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

44,332

Previous 44,638 0.69%

Holding current value

$22.3 Million

Previous $18.7 Million 11.36%

% of portfolio

0.12%

Previous 0.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $120,199 - $148,572	-306 Reduced 0.69%	44,332 $20.8 Million
Q1 2024 May 13, 2024	SELL	$407.69 - $446.08 $2.96 Million - $3.24 Million	-7,268 Reduced 14.0%	44,638 $18.7 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $44.3 Million - $53.1 Million	-129,266 Reduced 71.35%	51,906 $21.1 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $30.3 Million - $32.5 Million	89,685 Added 98.03%	181,172 $63 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $23.3 Million - $26 Million	73,987 Added 422.78%	91,487 $32.2 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $17.3 Million - $19.7 Million	-60,978 Reduced 77.7%	17,500 $5.51 Million
Q4 2022 Feb 24, 2023	BUY	$285.76 - $321.48 $5.59 Million - $6.29 Million	19,577 Added 33.24%	78,478 $22.7 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $10.2 Million - $11.4 Million	35,616 Added 152.96%	58,901 $17 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $2.53 Million - $2.82 Million	-9,232 Reduced 28.39%	23,285 $6.74 Million
Q2 2022 Aug 12, 2022	BUY	$234.96 - $292.55 $6.4 Million - $7.96 Million	27,221 Added 513.99%	32,517 $9.16 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $3.35 Million - $3.95 Million	-15,127 Reduced 74.07%	5,296 $1.38 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $29.5 Million - $37.2 Million	-166,652 Reduced 89.08%	20,423 $4.49 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $33.9 Million - $38 Million	187,075 New	187,075 $33.9 Million
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $11.3 Million - $13.3 Million	-60,011 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $462,275 - $538,845	2,233 Added 3.86%	60,011 $12.9 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $7.77 Million - $10.4 Million	37,522 Added 185.24%	57,778 $13.7 Million
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $716,586 - $849,589	-2,803 Reduced 12.16%	20,256 $5.51 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $3.05 Million - $4 Million	13,516 Added 141.63%	23,059 $6.69 Million
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $11.4 Million - $14.1 Million	-57,072 Reduced 85.67%	9,543 $2.27 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $19.9 Million - $26.7 Million	-119,454 Reduced 64.2%	66,615 $14.6 Million
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $4.91 Million - $5.52 Million	29,516 Added 18.85%	186,069 $31.5 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $17.8 Million - $20.5 Million	107,947 Added 222.09%	156,553 $28.7 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $50.8 Million - $60.4 Million	-310,306 Reduced 86.46%	48,606 $8.87 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $29.9 Million - $37.8 Million	196,919 Added 121.56%	358,912 $59.5 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $27.2 Million - $31.2 Million	161,993 New	161,993 $31.2 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $74 Million - $86.4 Million	-487,993 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $64.2 Million - $72.8 Million	467,713 Added 2306.28%	487,993 $73.1 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $2.15 Million - $2.36 Million	14,547 Added 253.74%	20,280 $3.08 Million
Q2 2017 Aug 14, 2017	BUY	N/A	5,733	5,733 $739,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account